כל המחקרים
גיוסPHASE2, PHASE3התערבותי

A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents With Fabry Disease

This study is looking into a new medicine called PRX-102 for children and teenagers (aged 2 to 17) who have Fabry disease. Fabry disease is a rare condition that can affect many parts of the body. PRX-102 is designed to act like a natural enzyme that's missing or not working properly in people with Fabry disease. Researchers want to find out the safest and most effective dose for young people. They will also check if PRX-102 helps improve common symptoms like pain, and how it affects important organs such as the kidneys and heart. About 20 to 22 young people will take part, receiving the medicine through a drip every two weeks.

במבט חטוף

סטטוס
גיוס
שלב
PHASE2, PHASE3
נותן חסות
Chiesi Farmaceutici S.p.A.
יעד הרשמה
22
התחל
29 יולי 2025
השלמה משוערת
01 Apr 2031

על מה המחקר הזה?

This study is designed to learn more about a new medicine called PRX-102 for children and teenagers who have Fabry disease. Fabry disease is a rare genetic condition where the body can't break down a certain type of fatty substance. This build-up can cause problems in many parts of the body, including the kidneys, heart, skin, and nervous system, leading to pain and other symptoms.

PRX-102 is a type of 'enzyme replacement therapy'. This means it's designed to replace the natural enzyme that's missing or not working correctly in people with Fabry disease. The medicine is given directly into a vein (like a drip) every two weeks. The main goals of this study are to work out the safest and most effective amount (dose) of PRX-102 for young people, and to see if it helps with common Fabry symptoms, such as pain, stomach problems, and how well the kidneys and heart are working.

Around 20 to 22 boys and girls between 2 and 17 years old with Fabry disease will be invited to take part. They will be split into different age groups for the study. The study has three main parts: first, finding the right dose for children; second, confirming how safe and effective that dose is; and finally, an optional long-term part where participants can continue receiving the treatment until it's widely available or the study ends.

נקודות עיקריות

  • This study is testing a new medicine, PRX-102, for young people with Fabry disease.
  • It aims to find the safest and most helpful dose for children and teenagers.
  • PRX-102 is given every two weeks through a drip into a vein.
  • Participants will have regular check-ups and tests during the study.
  • The study assesses effects on symptoms like pain, and organ function (heart, kidneys).

מי עשוי להיות זכאי?

To join this study, children and teenagers usually need to be between 2 and 17 years old and have a confirmed diagnosis of Fabry disease. They should also be experiencing some typical signs of Fabry disease, such as nerve pain, specific eye changes, or red spots on the skin (angiokeratoma). Importantly, their doctor must believe that they would benefit from this type of enzyme replacement treatment.

There are also some reasons why someone might not be able to join. For example, if they have certain kidney problems, or have had a serious allergic reaction to similar treatments in the past. If they are taking another experimental medicine, or have certain severe heart conditions, or have had COVID-19 recently, they might also not be able to participate. The study will also check for other health issues that could make taking part unsafe.

האם מחקר זה יכול להתאים לך?

ענה על השאלות המהירות הללו כדי לבדוק אם אתה עשוי להיות זכאי. זהו מדריך בלבד — צוות המחקר מקבל את ההחלטה הסופית.

  1. Is your child between 2 and 17 years old?
  2. Does your child have a confirmed diagnosis of Fabry disease?
  3. Does your child experience nerve pain, specific eye changes, or skin spots due to Fabry disease?
  4. Has your child ever had a severe allergic reaction to similar medicines?
  5. Does your child have certain severe heart or kidney conditions?
  6. Is your child currently taking part in another experimental medical study?
ענה על כל שאלה כדי לראות את התוצאה שלך.

מה כרוך בהשתתפות?

If your child takes part in this study, they will receive the study medicine, PRX-102, through a drip into a vein. This will happen at a clinic visit at least every two weeks. These visits will last for a few hours and will also include various tests to check their health and how the medicine is working.

These tests may include a physical examination, checking their heart with an ECG and ultrasound, and completing questionnaires about their symptoms, pain levels, and quality of life. Blood and urine samples will also be collected. The total duration of participation will vary. The initial stages involve researchers finding and confirming the right dose. An optional longer-term stage means some participants could continue on the treatment until it's available more widely or the study finishes.

סיכונים ותועלות פוטנציאליים

Taking part in any medical study has potential benefits and risks. A possible benefit of this study is that PRX-102 might help improve your child's Fabry disease symptoms or slow down its progression. However, we don't know for sure if it will be effective or safe in the long term, as it's still being investigated. Potential risks include side effects from the medicine, or discomfort from the regular blood tests and infusions. All possible side effects will be carefully monitored. You have the right to withdraw your child from the study at any time, for any reason, without it affecting their future medical care.

מיקומים (12)

  • Phoenix Children's
    מיקוד מאומת
    פניקס, ארצות הברית· גיוס
  • Emory Genetics Clinical Trials Center
    מיקוד מאומת
    אטלנטה, ארצות הברית· גיוס
  • University of Iowa
    מיקוד מאומת
    איווה סיטי, ארצות הברית· גיוס
  • מרכז רפואי בית חולים לילדים סינסינטי
    מיקוד מאומת
    סינסינטי, ארצות הברית· גיוס
  • University of Utah
    מיקוד מאומת
    סולט לייק סיטי, ארצות הברית· גיוס
  • Lysosomal and Rare Disorders Research and Treatment Center Inc
    מיקוד מאומת
    פיירפקס, ארצות הברית· גיוס
  • UK für Kinder- und Jugendheilkunde der PMU Salzburg
    מיקוד מאומת
    זלצבורג, אוסטריה· גיוס
  • Centre Hospitalier Universitaire (CHU) de Bordeaux - Groupe Hospitalier Pellegrin
    מיקוד מאומת
    בורדו, צרפת· גיוס
  • Hopital Arnaud de Villeneuve
    מיקוד מאומת
    מונפלייה, צרפת· גיוס
  • Haukeland Universitetssjukehus
    מיקוד מאומת
    Bergen, Norway· גיוס
  • Hospital Clinico Universitario De Santiago De Compostela
    מיקוד מאומת
    Santiago de Compostela, Spain· גיוס
  • Great Ormond Street Hospital for Children NHS Foundation Trust
    מיקוד מאומת
    לונדון, הממלכה המאוחדת· עדיין לא מגייסים

שאלות נפוצות

What is Fabry disease?

Fabry disease is a rare genetic condition where the body cannot properly break down a certain fat, leading to it building up in various organs like the kidneys, heart, and nerves.

How is PRX-102 given?

PRX-102 is given through a drip (intravenous infusion) into a vein, typically every two weeks at a clinic.

מי יכול להשתתף במחקר זה?

Children and teenagers aged 2 to 17 with a confirmed diagnosis of Fabry disease may be eligible, provided they meet other health criteria specified by the study.

כמה זמן יימשך המחקר?

The study has several stages, including dose-finding and confirmation. There's also an optional long-term extension, so the total time individual participants are involved can vary.

Will my child get the actual medicine or a dummy treatment?

In this specific study, all participants will receive the study medicine, PRX-102. There isn't a comparison group receiving a placebo (dummy treatment).

כיצד לגלות עוד

Chiesi Clinical Trial

תמיד התייעץ עם רופא המשפחה או המומחה שלך לפני שתחליט להשתתף במחקר.

מעוניינים להשתתף?

רשום את התעניינותך

שתף את הפרטים שלך וצוות המחקר עבור "A Study to Learn About the Safety and Effects of the Study D…" ייצרו איתך קשר אם אתה עשוי להיות זכאי. תמיד התייעץ עם הרופא שלך לפני שאתה מסכים להשתתף.

דיון

דיון קהילתי

מופעל על ידי הפורום שלנו ב community.patient.info. אנא היו מכבדים — זה אינו ייעוץ רפואי.